A newly designed drug passes through a long and tough route before reaching the market, and throughout its way, the safety, efficacy, and quality are the most compellable issues. Although the drugs are tested very elaborately for their safety in addition to their efficacy during preclinical and clinical trials, some concerns, such as difficulties in extrapolating drug data from animal to man, sample size that is required to emphasize to assess clinical benefit, limited duration in relatively healthy adults, and detection of rare adverse drug reactions (ADRs) and drug interactions, remain as problems to overcome. During preclinical and clinical studies, as well as post-marketing surveillance, the drug must satisfy all safety and efficacy concerns to launch and remain in the pharmaceutical market. These concerns are addressed by the system of pharmacovigilance, the partners of which are health authorities, hospitals, academia, healthcare professionals, pharmaceutical industry, and patients. A meta-analysis published by Lazarou et al. \[[@ref1]\] reported that ADRs are responsible for \>100,000 deaths and 2 million hospital admissions, making them between the fourth and sixth most common causes of death. This prevalence of ADR-related problems also revealed the requirement for national pharmacovigilance systems in the last decades. Although the pharmacovigilance data collected in developed countries initially appeared appropriate for extrapolation to other countries, the role of many confounding factors, primarily cultural and genetic predisposition, has proven the fallacy of this practice.

Therefore, the World Health Organization (WHO) recommends every country to establish their own pharmacovigilance systems and become full members of the WHO Programme for International Drug Monitoring. As of September 2017, this program has 127 participating member countries, and further 29 countries are associate members whose national pharmacovigilance centers are under establishment \[[@ref2]\].

Despite the establishment of the Turkish regulatory system in 1985 and membership in the WHO Programme for International Drug Monitoring since 1987, effective oversight and monitoring commenced in 2005 with the establishment of the Turkish Pharmacovigilance Centre (TUFAM), which became responsible for detecting post-marketing drug safety problems \[[@ref3]\].

In the present study, particular emphasis was placed on cardiovascular ADRs due to many concerns; because of being among the potentially life-threatening conditions and, due to their wide prevalence, being the fourth reason for withdrawal (n=61), after hepatotoxicity (n=81), immune-related reactions (n=79), and neurotoxicity (n=76). Moreover, the treatment options for negative cardiovascular effects are either lifelong or cured with major surgery, which both impart a severe medical, psychological, and economic burden on the patient, as well as additional costs on the healthcare system \[[@ref4], [@ref5]\].

The objective of the present study was to evaluate drugs withdrawn due to their cardiovascular risks, as well as cardiovascular drugs that were removed from the pharmaceutical market due to adverse effects either related or unrelated to their own pharmacological action worldwide between the period of 1950 and 2017.

METHODS {#sec1-2}
=======

In the present study, detailed web-based data search and concurrent systematic reviews that summarize all removed drugs worldwide have been conducted \[[@ref4], [@ref6], [@ref7]\]. Taking the above statement into account, our review updates and evaluates the data on drugs related to the cardiovascular system. The reputable sources given below compile a list of withdrawn cardiovascular drugs and drugs withdrawn for their cardiovascular concerns:

WHO's Drug Information (volumes 1--30)The WHO's Pharmaceutical Newsletters (1997--2017)The UK Medicine and Healthcare Products Regulatory Agency websiteThe UK Medicine and Healthcare Products Regulatory Agency, Drug Safety Monthly Updates (January 2015--May 2017)The US Food and Drug Administration (FDA) websitePubMedRecords of Turkish Medicines and Medical Devices AgencyEuropean Medicines Agency (EMA) website.

Veterinary medicines and drugs removed due to commercial reasons by pharmaceutical companies were not included in our data.

RESULTS {#sec1-3}
=======

A total of 464 drugs were withdrawn from 88 different pharmacological classes by 2017 according to our recent research. Of the 464 withdrawn drugs, 53 had cardiovascular indications ([Table 1](#T1){ref-type="table"}). There were 11 different pharmacological classes, namely antihypertensives, vasodilators, antilipidemics, antianginals, antiarrhythmics, antithrombotics, anticholesterol agents, cardiac stimulants, thrombolytics, vasopressors, and prostaglandins as shown in [Figure 1](#F1){ref-type="fig"}.

###### 

Cardiovascular drugs removed from the market due to adverse drug reactions between 1950 and 2017

  Medicinal product                                        Class               Therapeutic indication                       Reason for withdrawal                                                          Total years in the market
  -------------------------------------------------------- ------------------- -------------------------------------------- ------------------------------------------------------------------------------ ---------------------------
  Adenosine phosphate                                      Antiarrhythmic      Cardiac arrhythmia                           Cardiovascular                                                                 43
  Aliskiren                                                Antihypertensive    Hypertension                                 Angioedema                                                                     4
  Amoproxan                                                Antianginal         Angina                                       Sensory systems, skin                                                          1
  Beclobrate                                               Antilipidemic       Hyperlipidemia                               Hepatotoxicity                                                                 5
  Benzarone                                                Thrombolytic        Varicose veins                               Liver                                                                          28
  Bepridil                                                 Antiarrhythmic      Cardiac arrhythmia                           Cardiovascular                                                                 23
  Buflomedil                                               Vasodilator         Peripheral arterial occlusive disease        Neurotoxicity, cardiotoxicity                                                  36
  Cadralazine                                              Antihypertensive    Hypertension                                 Immunologic                                                                    3
  Cerivastatin                                             Antilipidemic       Hyperlipidemia                               Renal, musculoskeletal                                                         4
  Cinepazide                                               Vasodilator         Cerebrovascular disease                      Hematologic                                                                    14
  Clofibrate                                               Antilipidemic       Hyperlipidemia                               Accelerated deaths                                                             11
  Cyclandelate                                             Vasodilator         Raynaud's disease                            Not effective for use                                                          9
  Diethyl-aminoethoxyexestrol                              Antianginal         Angina pectoris                              Liver                                                                          6
  Dilevalol                                                Antihypertensive    Hypertension                                 Liver                                                                          1
  Dinoprostone[\*](#t1f1){ref-type="table-fn"}             Prostaglandin       Induction of labor                           Fetal distress, uterine hypertonia                                             19
  Dofetilide                                               Antiarrhythmic      Cardiac arrhythmia                           Cardiovascular                                                                 5
  Drotrecogin alfa (activated)                             Antithrombotic      Sepsis                                       Insufficient evidence, bleeding risk                                           10
  Encainide                                                Antiarrhythmic      Cardiac arrhythmia                           Cardiovascular                                                                 6
  Erythrityl tetranitrate                                  Antihypertensive    Angina pectoris                              Insufficient evidence, skin                                                    43
  Flosequinan                                              Vasodilator         Congestive heart failure                     Death                                                                          1
  Gallopamil                                               Antiarrhythmic      Cardiac arrhythmia                           Not specified, cardiovascular                                                  18
  Gemfibrozil                                              Anticholesterol     Dyslipidemia                                 Negative benefit-to-harm balance                                               5
  Guanethidine                                             Antihypertensive    Hypertension                                 Sensory systems                                                                13
  Hexestrol bis                                            Vasodilator         Hypertension                                 Hepatotoxicity                                                                 17
  (β-diethylaminoethyl ether)                                                                                                                                                                              
  Hydrochlorothiazide + sotalol                            Antihypertensive    Hypertension                                 Cardiovascular, drug interactions                                              16
  Indoramin                                                Vasodilator         Benign prostatic hyperplasia, hypertension   Cardiovascular                                                                 30
  Isoprenaline                                             Cardiac stimulant   Bradycardia and heart block, asthma          Cardiovascular                                                                 43
  Laropiprant/nicotinic acid                               Antilipidemic       Facial flushing                              Higher frequency of non-fetal but serious side effects                         0
  Levarterenol                                             Vasopressor         Nonhemorrhagic shock                         Nervous, Cardiovascular                                                        69
  Lysine amidotrizoate[\*\*](#t1f2){ref-type="table-fn"}   Radiography         Vascular diagnosis                           Cardiovascular, hematologic, immunologic, urinary tract (safer alternatives)   20
  Metipranolol                                             Antihypertensive    Hypertension                                 Sensory systems (uveitis)                                                      5
  Mibefradil                                               Antihypertensive    Hypertension                                 Drug interactions, musculoskeletal                                             1
  Molsidomine                                              Antianginal         Angina pectoris                              Tumorigenicity                                                                 13
  Moxisylyte (thymoxamine uroalpha)                        Antianginal         Benign prostatic hyperplasia                 Liver                                                                          4
  Muzolimine                                               Antihypertensive    Hypertension                                 Nervous system                                                                 4
  Naftidrofuryl                                            Vasodilator         Intermittent                                 Cardiovascular,                                                                18
  oxalate (IV)                                                                 claudication                                 immunologic, liver, urinary tract                                              
  Nifedipine (10 mg)                                       Antihypertensive    Hypertension                                 Cardiovascular                                                                 21
  Pargyline                                                Antihypertensive    Hypertension                                 Interaction with tyramine                                                      16
  Pentosan polysulfate Sodium                              Antithrombotic      Cystitis, osteoarthritis                     Hematologic, thrombocytopenia                                                  29
  Perhexiline maleate                                      Antianginal         Angina pectoris                              Hypoglycemia, liver, musculoskeletal, nervous system                           11
  Phentolamine mesylate                                    Antihypertensive    Erectile dysfunction                         Carcinogenicity                                                                2
  Polidexide                                               Antilipidemic       Hyperlipidemia                               Oculomucocutaneous syndrome                                                    3
  Potassium canrenoate                                     Antihypertensive    Hypertension, ascites                        Carcinogenic                                                                   18
  Potassium nitrate                                        Antihypertensive    Hypertension                                 Tumorigenicity                                                                 80
  Practolol                                                Antihypertensive    Hypertension                                 Gastrointestinal, sensory systems, skin                                        11
  Prenylamine                                              Antianginal         Angina pectoris                              Cardiovascular: multifactorial ventricular tachycardia                         29
  Probucol[\*\*\*](#t1f3){ref-type="table-fn"}             Antioxidant         Hyperlipidemia                               Cardiovascular, Torsade de pointes                                             9
  Pronethalol                                              Antihypertensive    Angina pectoris                              Tumorigenicity                                                                 2
  Sitaxentan sodium                                        Antihypertensive    Pulmonary arterial hypertension              Hepatotoxicity                                                                 4
  Suloctidil                                               Vasodilator         Intermittent claudication                    Liver, hepatotoxicity                                                          10
  Tienilic acid (ticrynafen)                               Antihypertensive    Hypertension, kidney stones                  Liver, urinary tract                                                           4
  Tocainide                                                Antiarrhythmic      Cardiac arrhythmia                           Hematologic, agranulocytosis, aplastic anemia                                  5
  Triparanol                                               Antilipidemic       Hyperlipidemia                               Sensory systems, skin                                                          3

Dinoprostone is a prostaglandin that has a direct mechanism of action as a vasodilator;

Lysine amidotrizoate is a radiographic agent but it is used for vascular diagnosis;

Probucol is an antioxidant that acts as an anti-hyperlipidemic drug.

![Cardiovascular classes of withdrawn drugs.](NCI-6-196-g001){#F1}

In addition, a total of 61 medicinal products from 33 different pharmacological classes were subject to withdrawal due to cardiovascular adverse effects. Those most likely to cause cardiovascular toxicity were psychostimulants (n=8), analgesics (n=5), antiarrhythmics (n=5), antipsychotics (n=4), and vasodilators (n=3), with the remaining 36 drugs distributed among 28 classes as shown in [Figure 2](#F2){ref-type="fig"}. There were 13 drugs that were both cardiovascular agents and were withdrawn due to cardiovascular toxicity as shown in [Table 2](#T2){ref-type="table"}.

###### 

Cardiovascular drugs withdrawn due to their adverse effects on the cardiovascular system

  Medicinal product             Class               Reason for withdrawal
  ----------------------------- ------------------- --------------------------------------------------------
  Prenylamine                   Antianginal         Cardiovascular: multifactorial ventricular tachycardia
  Adenosine phosphate           Antiarrhythmic      Cardiovascular
  Bepridil                      Antiarrhythmic      Cardiovascular
  Dofetilide                    Antiarrhythmic      Cardiovascular
  Encainide                     Antiarrhythmic      Cardiovascular
  Gallopamil                    Antiarrhythmic      Not specified, cardiovascular
  Hydrochlorothiazide+sotalol   Antihypertensive    Cardiovascular, drug interactions
  Nifedipine (10mg)             Antihypertensive    Cardiovascular
  Isoprenaline                  Cardiac stimulant   Cardiovascular
  Buflomedil                    Vasodilator         Neurotoxicity, cardiotoxicity
  Indoramin                     Vasodilator         Cardiovascular
  Naftidrofuryl oxalate (IV)    Vasodilator         Cardiovascular, immunologic, liver, urinary tract
  Levarterenol                  Vasopressor         Nervous, cardiovascular

![Pharmacological classes of drugs withdrawn in response to their cardiovascular toxicity.](NCI-6-196-g002){#F2}

DISCUSSION {#sec1-4}
==========

The benefits provided by a medication might come with associated risks to health and well-being. Benefits must outweigh risks by a significant margin in all cases. The ideal medication should combine a high benefit--risk ratio, optimal treatment with the least number of medications, and affordable cost of treatment.

It is noteworthy that some of the withdrawn drugs remained in the market for long periods. For instance, potassium nitrate despite its tumorigenic effects remained as an antihypertensive agent in the market for 80 years.

In contrast, synthetic Coumarin (anticoagulant) and Laropiprant/nicotinic acid (antilipidemic) were both withdrawn within a year of their launch, which is a testament to the improvements in the ADR reporting mechanisms and the awareness and acceptance of the pharmacovigilance systems worldwide. In Turkey, withdrawals were done at the same time as the EMA or FDA withdrawals, except sibutramine, which was withdrawn in Turkey due to the efforts of the TUFAM a month ahead of the EMA and 8 months ahead of the FDA \[[@ref8]\].

At least 200 ADR reports are expected to be submitted per million individuals annually according to the WHO \[[@ref9]\]. ADR reports to the FDA between 2006 and 2014 have shown a 2.7-fold increase in the United States \[[@ref10]\]. These high rates of ADRs and the withdrawal of products even that had appeared as "good drugs" in the market for many years cause loss of confidence to both drugs and the health authorities \[[@ref6]\]. In the present study, most drugs were conventional drugs. On the other hand, the number of biotechnological drugs is increasing as both original products and biosimilar products due to the expiration of biopharmaceutical patents. The number of ADRs on VigiBase Data has exceeded 12 million by 2015 \[[@ref7], [@ref11], [@ref12]\], thus warranting increased awareness of pharmacovigilance.

Similarly, the EudraVigilance system, established by the EMA, systematically works to encourage reporting of potential ADRs in Europe. In response to systematic works, the number of submitted reports showed an increasing trend, and the number of reports submitted to the EudraVigilance system exceeded 1 million in 2015 \[[@ref13]\].

National centers, such as TUFAM, also play a significant role in increasing public awareness of drug safety. The legal time limit of submitting traced ADR reports to the TUFAM is restricted to 15 days. The annual number of ADR report submissions to the TUFAM follows an increasing trend between 2006 and 2013, with the number of reports increasing by 8.2 times during this interval. However, the elevation of the number of ADR reports (2600 reports in 2013) is not high enough to reach the point expected from a population of 75 million according to a study \[[@ref14]\]. Therefore, extensive collaboration between all partners of the pharmacovigilance system is necessary to ensure that a sufficient level of ADR reporting is achieved after marketing \[[@ref3]\].

There are multiple intrinsic and extrinsic factors that can determine the patient's response to any pharmaceutical agent. A meta-analysis by Hakkarainen et al. \[[@ref15]\] suggested that 45%--52% of ADRs are preventable. One significant intrinsic factor is the genetic make-up of the patient. The emerging field of pharmacogenomics can greatly facilitate the tailoring of a patient-specific dose regimen and aid in the reduction of ADRs occurring as the genetic make-up of each person is unique. He et al. \[[@ref16]\] showed a correlation between a functional polymorphism in the CYP3A4 gene and an increased risk of coronary heart disease in the study population.

The main target of both pharmacogenomics and pharmacovigilance is to understand the heterogeneity and the structure of the drug efficacy and safety distribution signals among the population. Although these two disciplines are synergistic conceptually and practically, these disciplines do not have a sensible convergence up to now \[[@ref17]\].

The current implementation of pre-licensing Phase III trials involves the participation of 500--10,000 individuals, followed by the full licensing of the drug for the market. Post-marketing studies, which succeed the launch of the drug, are optional under the current regime. In light of the pharmacovigilance concept, it has become necessary that drugs undergoing Phase III trials with at least 3000 individuals should only obtain a conditional approval, followed by compulsory post-marketing studies involving at least 30,000 individuals by taking ADR reports into consideration for newly discovered drug molecules, only after which the full license should be issued. Building on these considerations, health problems caused by ADRs can be highly mitigated \[[@ref18], [@ref19]\].

CONCLUSION {#sec1-5}
==========

In light of the above information, the existing drug safety procedures should be widely reconsidered. In conclusion, collaboration between the participants of the pharmacovigilance system is necessary to develop and maintain an effective system for detecting post-marketing safety risks to protect public health.
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